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CASE REPORT
Prostatic relapse of an undifferentiated 
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Abstract 
Background: Non-seminomatous germ cell tumours make up about 40 % of all germ cell tumours, which in turn are 
the most common tumours in men aged 15–44 years. Low risk stage I non-seminomatous germ cell tumours, which 
are confined to the testes, are commonly treated by orchiectomy and surveillance. Up to 20 % of patients with this 
diagnosis relapse, usually within 1–2 years of follow up, but very rarely after more than 5 years. The most common 
sites of relapse are the retroperitoneal lymph nodes, the mediastinum, and the lungs. We describe a case of relapse in 
the prostate over 20 years after initial diagnosis, which has not been described in the literature so far.
Case presentation: This report presents a 49-year-old white British man with relapsed testicular non-seminomatous 
germ cell tumour 22 years after initial treatment with orchidectomy only. He relapsed with a prostatic mass, haemato-
spermia and back pain. His prostate specific antigen levels were within normal range. Alpha feto-protein and lactate 
dehydrogenase levels were elevated, and his human chorionic gonadotrophin levels were normal. A biopsy con-
firmed undifferentiated malignant tumour, shown immunohistochemically to be a yolk sac tumour. The patient was 
initially treated with bleomycin, etoposide and cisplatin chemotherapy, but developed bleomycin-related pulmonary 
side effects after two cycles. His treatment was changed and he completed four cycles of chemotherapy by receiving 
two cycles of etoposide, ifosfamide, and cisplatin. Post treatment blood tumour markers were normal, but a follow up 
computed tomography showed a mass in the base of the prostate, the trigone and the left distal ureter which was 
surgically resected. The histology from the surgical resection was of necrotic tissue. The patient is now in follow up at 
3 years after treatment with no evidence of residual disease on computed tomography. His Alpha feto-protein, beta 
human chorionic gonadotrophin and lactate dehydrogenase levels are normal.
Conclusions: Very late relapse in stage I non-seminomatous germ cell tumours is extremely rare and the prostate is a 
highly unusual site of relapsed disease. For diagnosis of late relapse, this case confirms the value of serum biomarkers 
in germ cell tumours, in particular non-seminomatous germ cell tumours.
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Background
Non-seminomatous germ cell tumours (NSGCTs) 
constitute about 40  % of all germ cell tumours, which 
in turn are the most common tumours in men aged 
15–44  years [1]. After orchidectomy, the risk of relapse 
in stage I disease can be predicted by histological exami-
nation of the orchidectomy specimen for the presence of 
lymphovascular invasion. If this is absent the relapse risk 
is 20 %; if it is present the risk is 50 % [2–4]. This risk is 
accumulated mainly in the first 2  years. Later relapse is 
extremely rare [5–7]. The retroperitoneum is the most 
common site of relapse, followed by mediastinal, lung 
and pleural, and rarely pelvic lymph nodes [8]. In the 
case of relapse, the cure rates are 98–99  % due to the 
high sensitivity of NSGCTs to platinum based chemo-
therapy. Adjuvant retroperitoneal lymph node dissection 
and adjuvant chemotherapy have been shown to reduce 
relapse risk, but have side effects and cost implications, 
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and are considered mainly in high-risk patients [9]. Post 
treatment surveillance comprises of history, examination, 
measurement of the tumour markers beta human chori-
onic gonadotrophin (beta HCG) and alpha feto-protein 
(AFP), and radiological surveillance with chest radio-
graphs and computed tomography (CT) at regular inter-
vals. Radiological investigations and measurements of 
tumour markers, in cases with initially raised marker lev-
els, are the most important parts of the surveillance pro-
tocol [10]. There is no consensus regarding the number 
or frequency of CT scans on surveillance though results 
from the TE08 trial suggest 2 CT scans of the abdomen at 
3 and 12 months of follow-up may be sufficient [11, 12].
In contrast to the large majority of cases, we present a 
case of relapsed stage I NSGCT more than 20 years after 
orchidectomy without adjuvant therapy. This case is fur-
ther noteworthy due to the highly unusual site of relapse 
within the prostate.
Case presentation
A 49-year-old white British man presented to his Gen-
eral Practitioner and afterwards a Urologist with spon-
taneously resolving haematospermia, normal prostate 
specific antigen (PSA) and normal magnetic resonance 
imaging (MRI) of the prostate. His past medical history 
was remarkable for stage I NSGCT which was treated 
with orchidectomy 21 years previously. He took no reg-
ular medication. A year after resolution of the haema-
tospermia he developed nocturia, poor urinary flow, and 
a feeling of pressure on his rectum. This was associated 
with severe back pain, for which he had started simple 
analgesia. Examination and ultrasound investigation of 
the remaining testis was normal. His PSA level was in 
the normal range at 1.11 microg/L but his AFP level at 
that stage was grossly elevated at 7787  ng/mL (normal 
range <10 ng/mL) with an lactate dehydrogenase (LDH) 
level of 486 U/L (normal range 0–250  U/L). HCG and 
free beta HCG levels were normal at less than 2 and less 
than 0.2 U/L, respectively. CT at that point demonstrated 
a pelvic mass with associated enlarged pelvic lymph 
nodes, mild left hydronephrosis, and multiple pulmonary 
metastases up to a diameter of 1.7 cm. An MRI was sub-
sequently performed to better define the local anatomy 
prior to surgery. MRI demonstrated an extensive pros-
tatic tumour extending into bladder (Fig. 1a, b), seminal 
vesicles, rectum and left ureter causing hydronephrosis. 
The total volume of the prostate was elevated at 113 mL. 
Histopathology from bladder biopsy confirmed the diag-
nosis of an undifferentiated malignant tumour that from 
its immunoprofile (AFP, PLAP and CD117 positive, 
CD30 and OCT 3/4 negative), was diagnosed as meta-
static yolk sac tumour (Fig. 2). Due to the non-pulmonary 
visceral metastases in the prostate his disease fell into the 
high risk category and treatment with four cycles of bleo-
mycin, etoposide, cisplatin (BEP) chemotherapy was ini-
tiated. He received a nephrostomy for decompression of 
the hydronephrosis and completed the first two cycles of 
BEP chemotherapy, but then developed evidence of bleo-
mycin-related lung changes on chest radiography and CT. 
His treatment was changed to etoposide, ifosfamide, and 
cisplatin (VIP) chemotherapy and he completed another 
two cycles for a total of four cycles of chemotherapy. He 
did not have any long term effects from the bleomycin.
All tumour markers were within the normal range after 
completion of chemotherapy. A CT 3  months into fol-
low up, however, showed a residual mass of 2.7 cm in the 
Fig. 1 T2-weighted magnetic resonance images. a, b Axial and coronal T2-weighted magnetic resonance images demonstrate a heterogeneous 
high signal lesion in the left seminal vesicle and prostate gland. There is a urinary catheter in situ. The lesion is markedly different to the low signal 
lesion typically found in primary prostatic carcinoma
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base of the prostate, the trigone and the left distal ure-
ter which was surgically resected. The excision specimen 
showed necrotic tissue and small amounts of normal 
prostate tissue and fibrosis, but no evidence of tumour 
cells. The tumour markers at this point had completely 
normalised. The patient is now in follow up at 36 months 
after treatment with no evidence of residual disease on 
CT. His AFP, beta HCG and LDH levels are normal.
Conclusion
The incidence of relapse in stage I NSGCT later than 
2  years after surgery is very low. No large data sets are 
available on late relapse, but published case series sug-
gest, that the majority of relapses in non-seminoma 
patients occur in the first 10 years of follow up, with the 
retroperitoneum being the most common site of relapse, 
followed by the mediastinum, the lung and pleura, and 
rarely the pelvic lymph nodes [5, 6, 8, 13–16]. There are 
a few cases published for relapse of germ cell tumors 
>20 years after diagnosis [17, 18]. Reviewing the pathol-
ogy of relapses later than 2  years, Michael et  al. found 
teratoma was the most commonly identified histology 
followed by yolk sac. Unusual types of yolk sac tumor 
were found to cause differential diagnostic problems with 
non-germ cell carcinomas, especially as there were many 
different sites of relapse [14].
Two case reports are similar to this case, Arafat et  al. 
describe a case involving a patient with stage I NSGCT 
who relapsed with a retroperitoneal mass after 27 years 
[19] and Lattouf et al. a case of stage I NSCGT who pre-
sented with a seminal vesicle relapse after 20 years [20]. 
For seminoma combined with yolk-sac tumour, late 
relapse after 43 years of surveillance has been described 
[21]. Notably, the published literature on case series in 
seminoma suggests that late relapse beyond 10  years is 
more common than for non-seminomas [7, 8, 22].
The patient described in this report had relapsed dis-
ease after 22 years from a stage I NSGCT that had been 
treated with orchidectomy and surveillance. Therefore, 
this case is distinct from the majority of reports listed 
above due to its stage, protracted time to relapse and site 
of relapse.
The tumour marker alpha fetoprotein was grossly 
elevated at relapse and the tumour was visible on radio-
logical investigation. Current guidelines do not cover in 
detail the protocol for continuous follow up of patients 
with stage I non-seminoma due to the lack of quality evi-
dence [23, 24]. Surveillance is more rigorous at the start 
as most relapses are early-median time to relapse for 
NSGCT is around 6–9  months. This includes monitor-
ing of the tumour markers and radiological investigations 
[23, 24].
One case report is, of course, insufficient to inform 
the treatment and follow up guidelines. It does, however, 
confirm the value of tumour marker in diagnosis of very 
late relapsed non-seminoma. Furthermore, it establishes 
evidence that NSGCT can recur more than 20 years after 
initial treatment, and this can be in highly unusual sites 
such as the prostate. It also highlights the need to note 
the history of a previous germ cell tumour when late 
metastatic disease occurs, as the histological features of 
such tumours (particularly yolk sac tumours post chemo-
therapy) may not be typical of the primary tumour and 
may therefore be misinterpreted histologically.
Fig. 2 Histopathological characterisation. Analysis was performed on paraffin-embedded tissue using haematoxylin and eosin (HE) stained sec-
tions. a ×10 magnification showing benign prostatic glands (upper part of picture) and undifferentiated tumour with sheets of cells and small cystic 
spaces (lower part of picture). b ×40 magnification showing a normal benign prostatic gland (lower part of picture) and undifferentiated tumour 
(upper part of picture)
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 Written informed consent was obtained from the 
patient for publication of this case report and any accom-
panying images.
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